CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
NCT04017546 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2024-09-19
Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
Conditions
Interventions
- DRUG
-
CYC065
intravenous infusion
- DRUG
-
oral capsule
Sponsors & Collaborators
-
Cyclacel Pharmaceuticals, Inc.
lead INDUSTRY
Principal Investigators
-
Gautam Borthakur, MD · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-02
- Primary Completion
- 2022-11-15
- Completion
- 2023-04-05
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
NCT03404193 ·Status: TERMINATED ·Phase: PHASE2
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
NCT05287568 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
NCT03672695 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196 ·Status: RECRUITING ·Phase: PHASE1
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
NCT05317403 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
NCT05168904 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
NCT03826992 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
NCT05522192 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
NCT01085656 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067 ·Status: RECRUITING ·Phase: PHASE1
-
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
NCT03417154 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
NCT06474663 ·Status: WITHDRAWN ·Phase: PHASE1
-
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05263284 ·Status: SUSPENDED ·Phase: PHASE1
-
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
NCT02689440 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
NCT05464836 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03484520 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
NCT03069352 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115 ·Status: TERMINATED ·Phase: PHASE1
-
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT06399640 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
NCT01191801 ·Status: COMPLETED ·Phase: PHASE3
-
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT04789655 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
NCT03797261 ·Status: TERMINATED ·Phase: PHASE1
-
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03896269 ·Status: RECRUITING ·Phase: PHASE1